In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seeking Blockbuster, Genzyme Binds Polymer Developer GelTex

Executive Summary

Three years ago, Genzyme and GelTex teamed up to commercialize Renagel, the only calcium-free phosphate binding agent used to treat dialysis patients. Now, informed with clinical data showing that calcium plays a role in cardiovascular disease among dialysis patients, the companies have agreed upon a billion-dollar merger. If Renagel's new-found blockbuster expectations are met, the deal will give Genzyme the big-market drug it needs to propel earnings growth.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts